| 000 | 01661 a2200505 4500 | ||
|---|---|---|---|
| 005 | 20250517133346.0 | ||
| 264 | 0 | _c20180227 | |
| 008 | 201802s 0 0 eng d | ||
| 022 | _a1471-2407 | ||
| 024 | 7 |
_a10.1186/s12885-016-3001-y _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aPalshof, Jesper Andreas | |
| 245 | 0 | 0 |
_aTopoisomerase I copy number alterations as biomarker for irinotecan efficacy in metastatic colorectal cancer. _h[electronic resource] |
| 260 |
_bBMC cancer _c01 2017 |
||
| 300 |
_a48 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntineoplastic Agents, Phytogenic _xtherapeutic use |
| 650 | 0 | 4 | _aBiomarkers, Tumor |
| 650 | 0 | 4 |
_aCamptothecin _xanalogs & derivatives |
| 650 | 0 | 4 |
_aColorectal Neoplasms _xdrug therapy |
| 650 | 0 | 4 |
_aDNA Topoisomerases, Type I _xgenetics |
| 650 | 0 | 4 | _aDisease-Free Survival |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aGene Dosage |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aIrinotecan |
| 650 | 0 | 4 |
_aLiver Neoplasms _xsecondary |
| 650 | 0 | 4 |
_aLung Neoplasms _xsecondary |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aHøgdall, Estrid Vilma Solyom | |
| 700 | 1 | _aPoulsen, Tim Svenstrup | |
| 700 | 1 | _aLinnemann, Dorte | |
| 700 | 1 | _aJensen, Benny Vittrup | |
| 700 | 1 | _aPfeiffer, Per | |
| 700 | 1 | _aTarpgaard, Line Schmidt | |
| 700 | 1 | _aBrünner, Nils | |
| 700 | 1 | _aStenvang, Jan | |
| 700 | 1 | _aYilmaz, Mette | |
| 700 | 1 | _aNielsen, Dorte Lisbet | |
| 773 | 0 |
_tBMC cancer _gvol. 17 _gno. 1 _gp. 48 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1186/s12885-016-3001-y _zAvailable from publisher's website |
| 999 |
_c26774604 _d26774604 |
||